Organizations will investigate HIV constructs in nonhuman primates, cytokine genes as vaccine adjuvants, and anticancer therapies as well as optimize HIV vaccine design.
Inovio Biomedical reports that its wholly owned subsidiary, Genetronics, entered into separate deals with the NCI and International AIDS Vaccine Initiative (IAVI), to evaluate Inovio’s electroporation technology for the delivery of DNA vaccines. The technology is designed to enhance the potency of DNA-based immunotherapies and vaccines against infectious diseases and cancers.
The collaboration with the NCI, being conducted under a CRADA, will assess novel HIV constructs in nonhuman primates, cytokine genes as vaccine adjuvants, and possibly anticancer therapies delivered using Inovio’s electroporation-mediated DNA delivery tool.
The IAVI partnership will focus on optimizing HIV vaccine design. Experimental HIV vaccines will be screened in preclinical models to select the most efficacious design to advance to clinical testing.